CTLA4 and neoplasm: RP-2 is an enhanced-potency, HSV-1-based OV with the addition of GALV-GP-R- (enhances cell fusion and tumor lysis), an anti-CTLA4 antibody-like molecule (improves T-cell priming and activation), and a codon-optimized sequence of GM-CSF (for recruiting and activating DCs) [63,92].